That's too generalized approach to me. You have to look at each case individually. Let's assume HG/TN subgroup result is the truth, you have to try to figure out why. At minimum, GPNMB expression level definitely played role! So the drug's mechanism of action IS important factor here. The possible explanation is GPNMB typically expressed in tumor epithelium for TNBC, while non-TNBC might be expressed in stroma. The question is whether CDX011 works one way better than the other. These need to be further tested to get answer. Again to minimize the drug's mechanism of action in later trial only works after you have right sample size to draw better conclusion. This isn't the case here.
Market Data 
Markets 
AI
